Phase 3 N=1,315 Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)
Gout
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 59.1; 66.6; 13.0; 27.5 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=5,099 Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up — 12.9; 7.5 percentage of…
Phase 3 N=257 Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure
Heart Failure · Dyspnea
Primary: Dyspnea Improvement Measured by Likert Scale at 8 and 24 Hours — 20; 26 Participants — p=0.315
Phase 3 N=666 A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
Breast Neoplasms
Primary: Progression-Free Survival (PFS) as Assessed by the Investigator — 24.8; 14.5 Months — p=<0.000001
Phase 3 N=2,334 Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Overall Survival — 29.0; 30.0 months — p=0.08
Phase 3 N=231 Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Neurotoxicity · Pain · Peripheral Neuropathy
Primary: Change in Average Pain From Week 1 to Week 5, as Measured by the BPI-SF Average Pain Severity Item — 1.06; 0.34 units on a scale — p=0.003
Phase 3 N=463 Smoking Cessation for American Indians
Smoking Cessation
Primary: 7-Day Point Prevalence Abstinence From Smoking for 6 Months — 49; 26; 26; 15 Participants
Phase 3 N=56 Add on Lacosamide Versus High Dose Monotherapy
Epilepsy
Primary: Percentage of Participants Achieving Six Month Seizure Freedom — 47.4; 41.7 percentage of participants — p=0.49
Phase 3 N=4 Sorbent Therapy of the Cutaneous Porphyrias
Erythropoietic Protoporphyria
Primary: Photosensitivity, Assessed by Measuring the Number of Minutes of Sun Tolerance — 65.8 minutes
Phase 3 N=488 Child and Adolescent Anxiety Disorders (CAMS)
Anxiety Disorders · Social Phobia · Generalized Anxiety Disorder
Primary: Clinical Global Impression - Improvement Scale — 54.9; 59.7; 80.7; 23.7 percentage of participants
Phase 3 N=255 DHEA Against Vaginal Atrophy - 3-Month Efficacy Study
Vaginal Atrophy
Primary: Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear — 68.48; 65.72; 65.05; 66.86 Percentage of parabasal cells
Phase 3 N=1,100 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine
Poliomyelitis · Poliomyelitis Vaccines
Primary: Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3 — 306; 296; 306; 296 Participants
Phase 3 N=467 Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Number of Participants With Adverse Events — 143; 154; 26; 16 participants
Phase 3 N=37 Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Primary Immunodeficiency Diseases (PID)
Primary: Number of Related Systemic Adverse Events (Excluding Infections) — 59 adverse events
Phase 3 N=252 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
Central Retinal Vein Occlusion
Primary: Average Change in Visual Acuity (Letters) From Baseline to Month 1 Through Month 3 — 11.3; -2.7 Letters — p=<0.001